Zika Virus Infections (Infectious Disease) – Drugs in Development, 2021
- Pages: 258
- Published: December 2021
- Report Code: GMDHC13192IDB
Global Markets Direct’s, ‘Zika Virus Infections – Drugs In Development, 2021’, provides an overview of the Zika Virus Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Zika Virus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Zika Virus Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
– The report provides a snapshot of the global therapeutic landscape of Zika Virus Infections
– The report reviews pipeline therapeutics for Zika Virus Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Zika Virus Infections therapeutics and enlists all their major and minor projects
– The report assesses Zika Virus Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Zika Virus Infections
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Zika Virus Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Zika Virus Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
Activirosomes Ltd
Acuitas Therapeutics Inc
Akshaya Bio Inc
Altimmune Inc
Aravive Inc
Autonomous Therapeutics Inc
Bharat Biotech Ltd
Biken Co Ltd
BioCryst Pharmaceuticals Inc
BioNet-Asia Co Ltd
Biotron Ltd
BravoVax Co Ltd
CanSino Biologics Inc
Cidara Therapeutics Inc
Ciloa
Cocrystal Pharma Inc
Codagenix Inc
CycloLab Cyclodextrin Research and Development Laboratory Ltd
Emergent BioSolutions Inc
Emergex Vaccines Holding Ltd
Enesi Pharma Ltd
Ennaid Therapeutics LLC
Enyo Pharma SA
Eurocine Vaccines AB
Excivion Ltd
Expres2ion Biotechnologies ApS
GeneOne Life Science Inc
GeoVax Labs Inc
Greffex Inc
Grifols SA
Hawaii Biotech Inc
Heat Biologics Inc
Hercules Pharmaceuticals BV
IDBiologics Inc
ImmunityBio Inc
Imutex Ltd
IMV Inc
Indian Immunologicals Ltd
Inovio Pharmaceuticals Inc
iosBio Pharma Ltd
Island Pharmaceuticals
Johnson & Johnson
Kamada Pharmaceuticals
KM Biologics Co Ltd
Macrophage Therapeutics Inc
Medigen Inc
Meletios Therapeutics SAS
Microbiotix Inc
Moderna Inc
Moleculin Biotech Inc
NanoViricides Inc
Novalex Therapeutics Inc
Orgenesis Inc
Ostrich Pharma USA Inc
Palisades Therapeutics
Pharos Biologicals LLC
Plex Pharmaceuticals Inc
Precision Virologics Inc
ProtInhi BV
Replikins Ltd
Riboscience LLC
Sanofi
Sementis Ltd
Starpharma Holdings Ltd
Takeda Pharmaceutical Co Ltd
TechnoVax Inc
TenGen Biomedical Co
Themis Bioscience GmbH
Theravectys SA
Tiba Biotech LLC
Touchlight Genetics Ltd
Tychan Pte Ltd
VBI Vaccines Inc
VenatoRx Pharmaceuticals Inc
Vir Biotechnology Inc
Virocovax
Xenothera SAS
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.